

Company Overview

HJLI specializes in developing and manufacturing bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has three product candidates: the porcine tissue based VenoValve®, which is intended to be surgically implanted in the deep venous system of the leg to treat Chronic Venous Insufficiency; the CoreoGraft®, a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery, and a porcine tissue based heart valve, which based upon its relatively small size and increased output, is an ideal candidate for pediatric aortic/mitral valve replacement.

Hancock Jaffe Successfully Starts First-in-Human VenoValve Study

Feb 19 2019, 8:31 AM EST

Hancock Jaffe Announces Objectives for Upcoming CoreoGraft Study

Jan 28 2019, 8:00 AM EST

Dr. Marc H. Glickman to Present at 6th Israeli Vascular Access Conference

Jan 15 2019, 8:00 AM EST

Stock Overview

Symbol HJLI
Exchange Nasdaq
Market Cap 17.58m
Last Price \$1.50
52-Week \$1.33 - \$5.64

02/20/2019 04:00 PM EST

Investor Relations

MZ North America
Chris Tyson
Managing Director
T: 949-491-8235
HJLI@mzgroup.us

Management Team

Robert Berman

Chief Executive Officer and Director

Robert Rankin

Chief Financial Officer

Marc Glickman, M.D.

Senior Vice President and Chief Medical Officer

Benedict Broennimann, M.D.

Chief Medical Officer, Outside of United States

Chris Sarner

Vice President of Regulatory Affairs and Quality Assurance

Hancock Jaffe Laboratories, Inc.

70 Doppler
Irvine, CA 92618

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.